Vyome Q3 Loss Nearly Doubles Analyst Estimates as Revenue Misses Zero Bar
HIND is trading near its 52-week low of $1.529 (6.6% above the low).
Summary
Vyome posted a Q3 adjusted loss of 37 cents a share, well wider than the 20-cent consensus and below the -25 to -16 cent range analysts modeled. Revenue came in at $116 thousand against expectations of zero, and the net loss was $2.53 million. The miss lands alongside the 10-Q filed this evening, which showed the loss narrowing to $930,325 from $8,595,300 a year ago and cash rising to $6.96 million — but material weaknesses remain unremediated and going-concern language persists. The stock has already fallen 18.7% this quarter and 54.4% year-to-date, so the wider-than-expected loss reinforces an already weak setup for a micro-cap with a going-concern flag. The FDA's request for more data on the lead program remains the bigger swing factor for the thesis.
At the time of this announcement, HIND was trading at $1.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4M. The 52-week trading range was $1.53 to $5.88. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.